KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.Gastric CancerPMID 34480657PMC87329262022-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.Eur J HaematolPMID 34496096PMC92931992022-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Respir MedPMID 34506761无 PMCID2022-Jan0.95The study is a randomized Phase III trial of cyclophosphamide for idiopathic pulmonary fibrosis (a non-malignant condition), not an oncology trial. While it has a drug intervention and primary results, it fails the core oncology criterion. The primary endpoint (3-month mortality) is not a standard time-to-event efficacy endpoint as defined (OS, PFS, DFS, EFS, RFS, TTP, or KM/HR).待处理
Japanese cedar pollen sublingual immunotherapy is effective in treating seasonal allergic rhinitis during the pollen dispersal period for Japanese cedar and Japanese cypress.Allergol IntPMID 34509370无 PMCID2022-Jan0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Diabetes Obes MetabPMID 34514682PMC92932362022-Jan0.98未发现恶性肿瘤人群证据。待处理
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.Diabetes Obes MetabPMID 34514692PMC92931362022-Jan0.98未发现恶性肿瘤人群证据。待处理
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.Lancet Infect DisPMID 34529962PMC76133172022-Jan0.98未发现恶性肿瘤人群证据。待处理
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.Lancet Infect DisPMID 34529963PMC76133262022-Jan0.98未发现恶性肿瘤人群证据。待处理
Randomized Controlled Trial of a Dichoptic Digital Therapeutic for Amblyopia.OphthalmologyPMID 34534556无 PMCID2022-Jan0.98未发现恶性肿瘤人群证据。待处理
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.Lancet Infect DisPMID 34563277无 PMCID2022-Jan0.98未发现恶性肿瘤人群证据。待处理
Efficacy of mirabegron, a β3 -adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies.Int J UrolPMID 34605079PMC92934042022-Jan0.98未发现恶性肿瘤人群证据。待处理
Added Value of a Blinded Outcome Adjudication Committee in an Open-Label Randomized Stroke Trial.StrokePMID 34607469PMC87003182022-Jan0.98未发现恶性肿瘤人群证据。待处理
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.Ann OncolPMID 34624497无 PMCID2022-Jan0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.Breast CancerPMID 34661821PMC87328562022-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.Cancer SciPMID 34689382PMC87482142022-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.Br J CancerPMID 34711947PMC87275692022-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.Liver IntPMID 34717041PMC92991942022-Jan0.98未发现恶性肿瘤人群证据。待处理
Association of Baseline Patient-reported Health-related Quality of Life Metrics with Outcome in Localised Prostate Cancer.Clin Oncol (R Coll Radiol)PMID 34728131无 PMCID2022-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.J Am Soc NephrolPMID 34732509PMC87631802022-Jan0.98未发现恶性肿瘤人群证据。待处理
LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials.J Lipid ResPMID 34774485PMC89536562022-Jan0.98未发现恶性肿瘤人群证据。待处理
Does variability in automated perfusion software outputs for acute ischemic stroke matter? Reanalysis of EXTEND perfusion imaging.CNS Neurosci TherPMID 34786868PMC86736992022-Jan0.98未发现恶性肿瘤人群证据。待处理
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.Lancet Gastroenterol HepatolPMID 34798036无 PMCID2022-Jan0.95The study is a Phase III randomized controlled trial of a drug (etrolizumab) for ulcerative colitis, which is not a cancer (malignant neoplasm). Therefore, it is excluded based on the non-oncology criterion, regardless of other meeting criteria.待处理
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.Lancet Gastroenterol HepatolPMID 34798037无 PMCID2022-Jan0.95The study is a Phase III randomized controlled trial for a drug intervention in ulcerative colitis, which is not a human malignant neoplasm (oncology) condition. Furthermore, the primary efficacy endpoint is remission at week 62 (a binary outcome), not a time-to-event endpoint such as overall survival, progression-free survival, or disease-free survival analyzed via Kaplan-Meier methods or hazard ratios.待处理
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.Int J Clin OncolPMID 34800178PMC87328162022-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.Eur J CancerPMID 34801353无 PMCID2022-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment.HeadachePMID 34806783PMC92995882022-Jan0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.Adv TherPMID 34816373PMC87995672022-Jan0.98未发现恶性肿瘤人群证据。待处理
The radiotherapy quality assurance gap among phase III cancer clinical trials.Radiother OncolPMID 34838891PMC89006712022-Jan0.95The report is an analysis of radiotherapy quality assurance practices across phase III oncology trials. It does not present efficacy results of a specific drug-containing intervention trial with a primary/key secondary time-to-event endpoint (OS, PFS, etc.). It is a methodological review of QA across multiple trials, not an original result report of a single randomized trial with a drug intervention and a survival endpoint.待处理
How bilastine is used to treat allergic rhinitis and urticaria in children.ImmunotherapyPMID 34850647无 PMCID2022-Jan0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blind, parallel-group, phase 3, randomised controlled trial.Lancet Infect DisPMID 34856181无 PMCID2022-Jan0.98未发现恶性肿瘤人群证据。待处理
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.Lancet OncolPMID 34871550无 PMCID2022-Jan0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Endovascular Thrombectomy in Young Patients With Stroke: A MR CLEAN Registry Study.StrokePMID 34872339无 PMCID2022-Jan0.98未发现恶性肿瘤人群证据。待处理
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet OncolPMID 34914889无 PMCID2022-Jan1.00命中用户提供的消化道肿瘤阳性参考集。待处理
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.Lancet OncolPMID 34919827无 PMCID2022-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.Cancer MedPMID 34921525PMC87290612022-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and cost-effectiveness of task-shared care for people with severe mental disorders in Ethiopia (TaSCS): a single-blind, randomised, controlled, phase 3 non-inferiority trial.Lancet PsychiatryPMID 34921796PMC88728072022-Jan0.98未发现恶性肿瘤人群证据。待处理
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.Drug SafPMID 34928484PMC87638442022-Jan0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.Anticancer ResPMID 34969712无 PMCID2022-Jan0.95The record is a Phase III randomized controlled trial in oncology, but it reports only health-related quality of life outcomes, not the required survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes.待处理
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.Lancet HaematolPMID 34971577无 PMCID2022-Jan0.45The study is a Phase III randomized trial of a drug for acute graft-versus-host disease (GVHD) following HSCT for hematological malignancy. However, the primary efficacy endpoint is Overall Response Rate (ORR) at day 28, which is a binary outcome, not a time-to-event endpoint like OS, PFS, DFS, etc. No time-to-event endpoints are reported or mentioned in the abstract. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint.待处理
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.Lancet HaematolPMID 34971579PMC100722402022-Jan0.98未发现恶性肿瘤人群证据。待处理
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.Lancet HaematolPMID 34971581PMC90981602022-Jan0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial.Nat MedPMID 35013615PMC94062372022-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pyronaridine-artesunate or dihydroartemisinin-piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial.Lancet MicrobePMID 35028628PMC87211542022-Jan0.98未发现恶性肿瘤人群证据。待处理
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.J Immunother CancerPMID 35074904PMC87883162022-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials.Clin TherPMID 35086735无 PMCID2022-Jan0.98未发现恶性肿瘤人群证据。待处理
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.J Immunother CancerPMID 35101942PMC88047052022-Jan0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.BioDrugsPMID 35133617PMC88472432022-Jan0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.Mult Scler Relat DisordPMID 35158426无 PMCID2022-Jan0.98未发现恶性肿瘤人群证据。待处理
Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Analysis of Quality of Life during a Phase III Study.Int Arch Allergy ImmunolPMID 34515149PMC898502020220.98未发现恶性肿瘤人群证据。待处理
Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Efficacy Analysis of a Phase III Study Performed in Russia.Int Arch Allergy ImmunolPMID 34535609PMC898499720220.98未发现恶性肿瘤人群证据。待处理